The present invention relates to a cell line wherein the endogenous class I and/or class II HLA alleles are inactivated, the cell line further comprising (a) a polynucleotide encoding a first fluorescent marker under control of at least one STAT response element, and (b) an interleukin 2 (IL-2) receptor. The invention further relates to the use of said cell line for the identification of antigenic peptide and/or the identification of alloreactive T cell receptors.

Described herein are methods for reducing tissue resident memory T cells (TRM) in the skin, as well as a method for treating, ameliorating, and/or preventing autoimmune and inflammatory diseases or disorders in the skin. These methods include downregulating the expression of GSPT1 in the tissue resident T cells. Also described are methods for screening therapeutic targets for regulating T cell functions.

The present disclosure provides editable cell lines, including the use of gene editing proteins to produce the cell lines. The editable cell lines are able to express antibody constant regions that can serve as a platform for the antibody variable regions to produce customized antibody.

The present disclosure relates to cultivated Rosaceae plants, such as strawberries, blackberries, and raspberries, having an early flowering trait resulting from genetically engineered Terminal Flowering alleles (TFL1) or homologs thereof that reduce or knockout TFL1 protein function. The disclosure further teaches methods of producing the same.

The present disclosure includes methods, vectors, compositions and kits for in vivo editing of stem cells in a subject.

The present invention relates to a method for editing the genome of a cell, such as a yeast cell. The method of the present invention requires the cell to be contacted with at least one ribonucleoprotein, at least one donor-DNA construct and a selectable marker such that they are introduced into the cell. The present invention is especially suitable for multiplex genome editing of cells such as yeast cells. The current invention further relates to a composition, a cell obtainable by the method of the invention and a method for the production of a compound of interest.

Provided herein are compositions of conjugates of a guide RNA(s)-CRISPR Cas protein (RNP) complex. The conjugate comprises a guide RNA(s)-CRISPR Cas protein (RNP) complex and one or more molecules selected from PEG, non-PEG polymers, ligands for cellular receptors, lipids, oligonucleotides, polysaccharides and peptides and chemically linked to the Cas protein and/or guide RNA(s). The conjugates are delivered to targeted cells as RNP complexes, or formed in targeted cells from guide RNA conjugates and a mRNA or a viral vector encoding a Cas protein, or formed in targeted cells from a crRNA conjugates and a viral vector encoding both a Cas protein and a tracrRNA. Also provided are preparation methods and uses of these conjugates.

Guide RNAs and CRISPR/Cas systems targeting a C9orf72 gene, lipid nanoparticles or viral vectors comprising such CRISPR/Cas systems, and cells or animals comprising such CRISPR/Cas systems are provided. Methods of repressing transcription from a C9orf72 exon 1 A transcription start site and/or repressing transcription of sense and/or antisense transcripts that comprise the hexanucleotide repeat expansion sequence in a C9orf72 gene using the CRISPR/Cas systems are also provided, as well as use of the CRISPR/Cas systems in prophylactic and therapeutic applications for treatment and/or prevention of a C9orf72 hexanucleotide repeat expansion associated disease and/or for ameliorating at least one symptom associated with such disease.

This disclosure relates to methods treating cancer comprising administering to a subject in need thereof a lipid nanoparticle comprising a therapeutically effective amount of a CRISPR/Cas system comprising one or more nucleic acid sequences encoding one or more guide RNAs (gRNAs) that are complementary to one or more target sequences in a cancer gene of a cancer cell and a nucleic acid sequence encoding a CRISPR-associated endonuclease.

The present disclosure provides virus-like particles for delivering gene editing agents such as nucleic acid-programmable DNA-binding proteins (napDNAbps) and base editor fusion proteins (BE-VLPs or eVLPs), and systems comprising such eVLPs. The present disclosure also provides polynucleotides encoding the eVLPs described herein, which may be useful for producing said eVLPs. Also provided herein are methods for editing the genome of a target cell by introducing the presently described eVLPs into the target cell. The present disclosure also provides fusion proteins that make up a component of the eVLPs described herein, as well as polynucleotides, vectors, cells, and kits.